News coverage about Odonate Therapeutics (NASDAQ:ODT) has trended somewhat positive recently, according to Accern. The research group identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Odonate Therapeutics earned a media sentiment score of 0.05 on Accern’s scale. Accern also gave media stories about the company an impact score of 46.0258420329684 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
ODT has been the subject of several research analyst reports. Cowen initiated coverage on shares of Odonate Therapeutics in a research report on Tuesday, January 2nd. They issued an “outperform” rating for the company. Jefferies Group initiated coverage on shares of Odonate Therapeutics in a research report on Tuesday, January 2nd. They issued a “buy” rating and a $40.00 price target for the company. Goldman Sachs initiated coverage on shares of Odonate Therapeutics in a research report on Tuesday, January 2nd. They issued a “neutral” rating and a $27.00 price target for the company. Finally, Zacks Investment Research downgraded shares of Odonate Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, March 7th.
Odonate Therapeutics stock traded up $1.52 during trading hours on Tuesday, hitting $22.73. The company had a trading volume of 31,595 shares, compared to its average volume of 66,899. The firm has a market cap of $591.72 and a PE ratio of -9.77. Odonate Therapeutics has a fifty-two week low of $15.15 and a fifty-two week high of $32.00.
In related news, Director Boxer Capital, Llc acquired 100,000 shares of the company’s stock in a transaction on Monday, March 26th. The shares were purchased at an average price of $22.73 per share, for a total transaction of $2,273,000.00. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Kevin C. Tang acquired 39,083 shares of the company’s stock in a transaction on Thursday, February 22nd. The stock was bought at an average price of $27.17 per share, for a total transaction of $1,061,885.11. The disclosure for this purchase can be found here. In the last quarter, insiders acquired 310,000 shares of company stock worth $7,386,567.
COPYRIGHT VIOLATION WARNING: “Odonate Therapeutics (ODT) Earning Somewhat Positive News Coverage, Analysis Finds” was originally reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States and international trademark and copyright legislation. The original version of this story can be accessed at https://www.chaffeybreeze.com/2018/04/17/odonate-therapeutics-odt-earning-somewhat-positive-news-coverage-analysis-finds.html.
Odonate Therapeutics Company Profile
Odonate Therapeutics, Inc, a pharmaceutical company, develops therapeutics for the treatment of cancer. It focuses on the development of tesetaxel, an orally administered chemotherapy agent for patients with advanced or metastatic breast cancer (MBC). Odonate Therapeutics, Inc also conducting a Phase III study in MBC, which is known as CONTESSA.
Receive News & Ratings for Odonate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Odonate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.